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ABSTRACT
In total, 226 individuals from the community
were investigated for faecal carriage of Acinetob-
acter spp. by broth enrichment culture, followed
by growth on blood agar and ⁄ or Leeds Acinetob-
acter Medium (LAM). Acinetobacter baumannii was
isolated on both LAM and blood agar from one of
100 specimens in the UK and one of 126 speci-
mens in The Netherlands. The predominant
species were Acinetobactor johnsonii and genomic
sp. 11, which were cultured from 22 and ﬁve
specimens, respectively. A. baumannii did not
seem to be widespread in the faecal ﬂora of
individuals in the community.
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Acinetobacter baumannii is an increasingly import-
ant nosocomial pathogen which can cause major
outbreaks of infection. The organism is often
acquired nosocomially, but can be introduced
initially by patients admitted from other hospitals
[1]. Certain strains (clones) have been shown to be
distributed between hospitals in wide geograph-
ical areas [2–4]. However, the origin of a suddenly
appearing epidemic A. baumannii strain in a
hospital is often unknown, and it remains poss-
ible that A. baumannii has a reservoir in the non-
hospitalised human population, from which
strains can be introduced into a hospital. The
present study investigated the occurrence of
A. baumannii in faecal specimens from non-hos-
pitalised individuals in order to determine whe-
ther there is a signiﬁcant intestinal reservoir from
which spread to hospitals could occur. The study
was performed in Nottingham (UK) and Leiden
(The Netherlands), thus allowing comparison of
populations at two locations. In Nottingham, the
investigation focused exclusively on A. baumannii,
while in Leiden, the prevalence of other Acinetob-
acter spp. was also investigated.
In total, 226 individuals from the community
were investigated. One faecal specimen from each
individual was received from general practition-
ers for investigation of parasites or microbial
pathogens by the diagnostic laboratories at
Leiden University Medical Center and University
Hospital, Nottingham. A sterile cotton swab was
used to sample the faeces, and the material taken
up on the swab was transferred to ﬂasks contain-
ing 20 mL of acetate mineral medium [5]. The
samples were mixed to resuspend the faecal
material, and then incubated with vigorous aer-
ation for up to 48 h at 30C to enrich for
Acinetobacter spp. Following incubation, the cul-
tures were streaked on to Leeds Acinetobacter
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Medium (LAM) [6] and blood agar. The plates
were incubated aerobically at 30C and examined
after 24 h and 48 h for putative A. baumannii
colonies (pink with mauve background on LAM
[6]), or other colonies with a morphology on
blood agar that was typical of Acinetobacter
spp. (non-pigmented, white or cream-coloured,
smooth to mucoid colonies, 1–2 mm in diameter
[7]). One colony of each morphotype was selected
for species identiﬁcation.
Putative acinetobacters were identiﬁed pre-
sumptively to the genus Acinetobacter on the basis
of morphology following Gram’s stain (Gram-
negative coccobacilli), a negative oxidase reaction,
and the reactions included in the API 20NE
system (bioMe´rieux, Marcy-l’Etoile, France). Spe-
cies identiﬁcation was achieved by ampliﬁed
ribosomal DNA restriction analysis (ARDRA)
[8] and high-resolution genomic ﬁngerprinting
using ampliﬁed fragment length polymorphism
(AFLPTM) analysis [9], followed by comparison of
the restriction fragments and DNA ﬁngerprints
generated by these respective methods to those of
280 reference strains (collection of Leiden Univer-
sity Medical Center) belonging to all known
species of Acinetobacter. If ARDRA was not con-
clusive, additional tests based on the biochemical
identiﬁcation system of Bouvet and Grimont [10]
were used to achieve a ‘consensus’ identiﬁcation
[11]. Isolates from the same specimen with an
identical API 20NE proﬁle and ⁄ or indistinguish-
able AFLP ﬁngerprints were considered to repre-
sent the same strain, and only one of these was
included in the ﬁnal analysis.
The recovery rates of the different species are
shown in Table 1. InNottingham, faecal specimens
from 100 individuals were investigated, and only
colonies on LAM that resembledA. baumanniiwere
processed further. Only one of the three putative
Nottingham A. baumannii isolates on LAM was
identiﬁed deﬁnitively to this species; this isolate
was resistant only to ﬁrst-generation cephalospo-
rins, chloramphenicol and trimethoprim. The two
other isolates were considered not to beA. bauman-
nii following ARDRA and AFLP analysis. In
Leiden, 126 faecal specimens were investigated,
and all putative acinetobacters fromboth LAMand
blood agar were processed. In Leiden, 31 (24.6%)
specimens were positive for a variety of Acinetob-
acter spp. Only one sample yielded anA. baumannii
isolate (on both LAM and blood agar), which was
resistant to ﬁrst-generation cephalosporins only;
the predominant species wasA. johnsonii, followed
bygenomic sp. 11.A. johnsoniigrewmostly (17 of 22
specimens) on blood agar only.Genomic sp. 11was
recovered fromﬁve samples, ofwhich four grewon
LAM and blood agar, and one on LAM only. Four
Leiden specimens yielded two species each. One
specimen grew a putative Acinetobacter sp. which
could not be identiﬁed to any of the described
named or unnamed species.
The recovery rate (0.8%) of A. baumannii in
Leiden was in good agreement with that in
Nottingham (1.0%), which suggests that the
human intestine does not constitute an important
community reservoir of this organism. This low
isolation rate in the community contrasts with a
faecal colonisation rate of 41% among hospitalised
patients in an intensive care unit in Spain [12].
However, the present study only included indi-
viduals whose faeces were submitted for investi-
gation of possible intestinal pathogens, and this
was therefore not a random sample from the
community. Nevertheless, the ﬁndings were con-
sistentwith a previous study in 1978 [13] that failed
to ﬁnd glucose-acidifying acinetobacters (which
include A. baumannii) following enrichment
cultivation in stool samples from 50 individuals.
Several other studies have investigated the
possibility that human skin could be a community
reservoir of A. baumannii. Two studies using
enrichment cultivation and validated methods
for species identiﬁcation, one in the UK and one
in Germany, found A. baumannii carriage in only
one (0.5%) of 192 healthy volunteers in the UK
[14] and one (2.5%) of 40 healthy volunteers in
Germany [15]. A survey in Hong Kong yielded
A. baumannii, as identiﬁed by ARDRA, from
Table 1. Acinetobacter spp. cultured from faecal specimens
of 226 individuals in the UK and The Netherlands
Species
No. (%) of positive specimens
Nottingham, UKa
(n = 100)
Leiden, The Netherlandsb
(n = 126)
A. baumannii 1 (1.0) 1 (0.8)
Genomic sp. 3 – 1 (0.8)
A. junii 1 (1.0) 2 (1.6)
A. johnsonii 1 (1.0) 22 (17.5)
A. lwofﬁi – 1 (0.8)
A. ursingii – 2 (1.6)
Genomic sp. 10 – 1 (0.8)
Genomic sp. 11 – 5 (4.0)
aIn Nottingham, only putative A. baumannii colonies on Leeds Acinetobacter
Medium (LAM) were investigated.
bIn Leiden, all possible Acinetobacter spp. colonies on LAM and blood agar were
investigated; four specimens each yielded two different species; one specimen
yielded a putative Acinetobacter colony which could not be identiﬁed to any
Acinetobacter sp. described previously.
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4–12% of individuals in the community [16], and
a survey in New York (USA) found a hand
carriage rate of 10.4% in individuals from the
community [17]. However, these rates may be an
overestimation, since species identiﬁcation was
achieved only by phenotypic methods, which are
not sufﬁcient for unambiguous identiﬁcation of
A. baumannii [18]. In addition, typing of isolates in
the New York study [17] showed that the com-
munity isolates differed from those in hospitals in
the same area. Similarly, the two A. baumannii
isolates recovered in the present study were
far more susceptible to antimicrobial agents
than most hospital isolates. Other studies explor-
ing environmental reservoirs have recovered
A. baumannii, albeit infrequently, from vegetables,
meat, ﬁsh and soil [19,20]. A. baumannii has also
been isolated from lice colonising homeless indi-
viduals, with the suggestion that the organisms
originated from the blood of the host [21].
In conclusion, A. baumannii does not seem to be
widespread in non-hospitalised individuals, but it
can be recovered at low frequencies from skin and
faecal ﬂora, and from speciﬁc environmental sites.
Community-acquired infections with A. bauman-
nii in animals and humans have also been
reported [22,23]. However, although rare A. bau-
mannii strains could be introduced into hospitals
from non-hospitalised individuals and ⁄ or envi-
ronmental sources, further work is required to
determine whether strains from the community
have the capacity to become established and
spread among susceptible hospitalised patients.
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ABSTRACT
Of 233 erythromycin-resistant pneumococcal iso-
lates collected in Belgium in 1999–2000, 89.7%
carried the erm(B) gene, 6% the mef(A) gene, and
3.5% erm(B) plus mef(A). Two isolates contained
neither erm(B) nor mef(A); one contained an
erm(A) subclass erm(TR) gene, while the other
contained an A2058G mutation in domain V of
the 23S rRNA gene. Of 209 erm(B)-positive iso-
lates, 191 had clindamycin MICs > 16 mg ⁄L and
18 had MICs £ 16 mg ⁄L. Mef(A)-positive isolates
all displayed the M resistance phenotype. Telith-
romycin remained active against erythromycin-
resistant isolates, with the highest telithromycin
MIC50 being found in mef(A)-positive isolates. No
difference in the prevalence of different resistance
mechanisms was observed compared to isolates
collected in 1995–1997.
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Erythromycin resistance in pneumococcal isolates
from Belgium increased from 5.5% in 1986 to 37%
in 2003 [1]. Macrolides are still used extensively in
Belgium, despite a consensus that they are not the
ﬁrst-choice therapy for respiratory tract infections
in adults. As the data suggest that macrolides
may drive b-lactam resistance, it remains import-
ant to monitor macrolide resistance [2].
Pneumococcal macrolide resistance can be
caused by erm(B) (erythromycin ribosome methy-
lase)-encoded methylation of a residue in the 23S
rRNA [3]. Phenotypically, this results in the MLSB
resistance phenotype, with resistance to all
macrolides plus lincosamides and streptogramin
B antibiotics. An alternative resistance mechanism
involves mef(A) (macrolide efﬂux), resulting in
M-type resistance to 14- and 15-membered macro-
lides, but not to 16-membered macrolides, lincos-
amides or streptogramin B antibiotics. The
simultaneous presence of mef(A) and erm(B) has
been reported [4], while other reports have
described mutations in regions V and II of the
23S rRNA gene, and also in genes encoding
riboproteins L4 and L22. Resistance phenotypes
correlating with these mutations may vary [5,6].
Two studies examined erythromycin resistance
in pneumococci collected from Belgium in
1995–1997, and showed that resistance was asso-
ciated predominantly with erm(B)- and rare
mef(A)-positive isolates [7,8]. In the present study,
637 Streptococcus pneumoniae isolates obtained
from clinical samples (respiratory, blood, cere-
brospinal ﬂuid) in Belgium between October 1999
and February 2000 were investigated.
Antibiotic susceptibility was determined by
adding doubling dilutions (0.008–16 mg ⁄L) of
antibiotics to molten Mueller–Hinton agar (Oxoid,
Basingstoke, UK) supplemented with horse blood
5% v ⁄v. Multipoint inoculation was in duplicate,
with 104 CFU ⁄ spot, followed by incubation for
24 h at 36C in CO2 5% v ⁄ v. NCCLS breakpoints
were used for interpretation of the results. Anti-
biotics were provided by their respective manu-
facturers.
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